188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples